Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.
Also called NCT01059825
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 375 participants
- Sponsor
- Registry
-
NCT01059825 -
2009-017131-18
-
- Other papers using this trial's data
- Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01059825. Randomized; double masking; primary purpose treatment. Start 2010-02-24 (actual); primary completion 2011-01-20 (actual). Results posted on 2017-10-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo to Ertugliflozin
- Intervention (Drug)
- Ertugliflozin 1 mg
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Ertugliflozin 25 mg
- Intervention (Drug)
- Sitagliptin 100 mg
- Intervention (Drug)
- Placebo to Sitagliptin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct01059825- Content hash
ffd4a1afc7a5f1f5c1071c64220985652f91c8356564c07c10e130e2cf41a35a